Core Scientific (CORZ) Common Equity (2020 - 2026)

Core Scientific has disclosed Common Equity across 7 years of filings, most recently posting -$2.4 billion for Q2 2026.

• In Q2 2026, Common Equity fell 102.97% year-over-year to -$2.4 billion; the TTM figure through Jun 2026 stood at -$2.4 billion (down 102.97% YoY), while the FY2025 annual figure was -$962.7 million, down 2.09% from the prior year.
• Common Equity came in at -$2.4 billion for Q2 2026 at Core Scientific, down from -$1.3 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.1 billion in Q1 2022 to a low of -$2.4 billion in Q2 2026.
• Average Common Equity over 5 years is -$628.3 million, with a median of -$507.8 million recorded in 2023.
• Year-over-year, Common Equity soared 1059.68% in 2022 and sank 673.39% in 2023.
• Over 5 years, Common Equity stood at -$409.3 million in 2022, then plunged by 45.83% to -$596.9 million in 2023, then slumped by 57.98% to -$943.0 million in 2024, then declined by 2.09% to -$962.7 million in 2025, then tumbled by 151.3% to -$2.4 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$2.4 billion in Q2 2026, -$1.3 billion in Q1 2026, and -$962.7 million in Q4 2025.